PMID- 36127309
OWN - NLM
STAT- MEDLINE
DCOM- 20230412
LR  - 20230428
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 24
IP  - 4
DP  - 2023 Apr
TI  - Comparison between the impact of tenofovir alafenamide and that of abacavir on 
      rapid kidney function decline: A retrospective observational study.
PG  - 422-430
LID - 10.1111/hiv.13408 [doi]
AB  - OBJECTIVES: To compare the impact of tenofovir alafenamide (TAF) on the slope of 
      the estimated glomerular filtration rate (eGFR) with that of abacavir in Japanese 
      patients living with HIV infection. METHODS: The participants in this 
      single-centre, retrospective, observational study were Japanese patients with HIV 
      infection who started antiretroviral therapy with TAF/emtricitabine or 
      abacavir/lamivudine or were switched from tenofovir disoproxil 
      fumarate/emtricitabine to TAF/emtricitabine or abacavir/lamivudine (anchor drugs 
      remained constant) between January 2012 and December 2020. The eGFR slope was 
      defined as the regression coefficient between eGFR and time. The study outcome 
      was rapid kidney function decline (RKFD; eGFR slope < -5 mL/min/1.73 m(2) /year). 
      The adjusted effect of TAF on the eGFR slope was compared with that of abacavir 
      using multivariate logistic regression analysis. RESULTS: The study included 184 
      patients (with 2835 eGFR data points). The median duration of exposure to TAF or 
      abacavir was 2.6 years [interquartile range (IQR): 1.7-3.3], and the median eGFR 
      slope was -4.1 mL/min/1.73 m(2) /year (IQR: -6.4 to -1.2). In all, 72 patients 
      (39%) experienced RKFD. Patients receiving TAF were more likely to experience 
      RKFD (adjusted odds ratio = 3.74) than those receiving abacavir. There was a 
      significant independent association between baseline eGFR and RKFD. CONCLUSIONS: 
      These findings suggest that renal function should be monitored carefully after 
      the initiation of TAF in Japanese patients with HIV infection.
CI  - (c) 2022 British HIV Association.
FAU - Hikasa, Shinichi
AU  - Hikasa S
AUID- ORCID: 0000-0002-4850-7631
AD  - Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Japan.
FAU - Shimabukuro, Shota
AU  - Shimabukuro S
AD  - Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Japan.
FAU - Hideta, Kyoko
AU  - Hideta K
AD  - Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Japan.
FAU - Higasa, Satoshi
AU  - Higasa S
AD  - Department of Respiratory Medicine and Hematology, Hyogo Medical University, 
      Nishinomiya, Japan.
FAU - Sawada, Akihiro
AU  - Sawada A
AD  - Department of Respiratory Medicine and Hematology, Hyogo Medical University, 
      Nishinomiya, Japan.
FAU - Tokugawa, Tazuko
AU  - Tokugawa T
AD  - Department of Respiratory Medicine and Hematology, Hyogo Medical University, 
      Nishinomiya, Japan.
FAU - Tanaka, Kuniyoshi
AU  - Tanaka K
AD  - Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Japan.
FAU - Yanai, Mina
AU  - Yanai M
AD  - Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Japan.
FAU - Kimura, Takeshi
AU  - Kimura T
AD  - Department of Pharmacy, Hyogo Medical University Hospital, Nishinomiya, Japan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20220920
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 2T8Q726O95 (Lamivudine)
RN  - 0 (Anti-HIV Agents)
RN  - WR2TIP26VS (abacavir)
RN  - JAC85A2161 (Adenine)
RN  - G70B4ETF4S (Emtricitabine)
RN  - 0 (Dideoxynucleosides)
SB  - IM
MH  - Humans
MH  - Lamivudine/adverse effects
MH  - *HIV Infections/drug therapy
MH  - *Anti-HIV Agents/adverse effects
MH  - Retrospective Studies
MH  - Adenine/adverse effects
MH  - Emtricitabine/therapeutic use
MH  - Dideoxynucleosides/adverse effects
MH  - Kidney
OTO - NOTNLM
OT  - HIV infection
OT  - abacavir
OT  - rapid kidney function decline
OT  - renal function
OT  - tenofovir alafenamide
EDAT- 2022/09/21 06:00
MHDA- 2023/04/12 06:42
CRDT- 2022/09/20 22:52
PHST- 2022/02/18 00:00 [received]
PHST- 2022/08/30 00:00 [accepted]
PHST- 2023/04/12 06:42 [medline]
PHST- 2022/09/21 06:00 [pubmed]
PHST- 2022/09/20 22:52 [entrez]
AID - 10.1111/hiv.13408 [doi]
PST - ppublish
SO  - HIV Med. 2023 Apr;24(4):422-430. doi: 10.1111/hiv.13408. Epub 2022 Sep 20.